Rosiglitazone's Effect And Signifcance On The Growth Of SMMC-7721 Cell Line And The Genetic Expression Of PTEN And Survivin

Objective:The hepatocellular carcinoma is one of the clinically common malignant tumors,which has high mortality and difficult to cure. It progresses fast,invade,transfer and recur easily. Along with the development of medical technology and medical research,the study on HCC develops increasingly, even to the level of gene. Many related tumor factors and anti-tumor factors has been found such as survivin,PTEN and so on. But at present the certain mechanism of HCC genesis is not clear,there is no effective protective measure yet. Thus it's greatly significant in clinic to research the etiopathogenesis of HCC and investigate new protective measure.Our experiment further reveal the possible mechanism of action on the inhibition of hepatoma growth by investigating the effect of rosiglitazone ( PPARγagent ) on the growth of SMMC-7721 hepatoma carcinoma cell line and the expression of survivin,PTEN.Methods : 1 Measurement of depressant effect of rosiglitazone on the growth of SMMC-7721 hepatoma carcinoma cell line by MMT method: SMMC-7721 hepatoma carcinoma cell line was cultured conventionally. We evaluated rosiglitazone's role on HCC by MTT. By analysis of variance for one factors (ANOVA), cell inhibition ratio was analysised to investigate time-effect relationship and quantity-effect relationship.2 we determined by Western Blot the protein expression of survivin and PTEN in four groups which were administered with rosiglitazone of various concentrations, 0. 1,1,10,100(μmol/L)respectively, and on three action times(24h,48h,72h)in each group. By analysis of variance for one factors (ANOVA), optical density was analysised to investigate time-effect relationship and quantity-effect relationship.Results:1 The research of rosiglitazone on SMMC-7721 hepatoma carcinoma cell line:The result by MMT method showed that rosiglitazone could inhibit cell proliferation of SMMC-7721 significantly. under inverted microscope, we found that more cells turned round and brighter, the cells of adherence is less, following the administration of rosiglitazone for 48h. The relationship between them is significantly time and concentration dependent(P<0.05).2 Detect the expression of PTEN,survivin by Western Blot: We determined the protein expression of survivin and PTEN in four groups which were administered with rosiglitazone of various concentrations, 0. 1,1,10,100(μmol/L)respectively, and on three action times(24h,48h,72h. No obvious difference of expression of surviving was found. And the expression of PTEN showed time dependent and dose dependent. Conclusion:1 The result by MMT method show that rosiglitazone impact markedly on inhibiting the growth of HCC. By upregulating the expression of anti-oncogene in HCC, rosiglitazone can inhibit proliferation of tumor, and promote apoptosis of tumor cell, thus get therapeutical effect. 2 The result by Western Blot show that rosiglitazone was not significantly related with the expression of surviving, but promoted the expression of PTEN, the relationship between them is time dependent and dose dependent. It shows that rosiglitazone perhaps do not inhibit the proliferation of SMMC-7721 by down-regulating survivn. Further researches about PPARγagonist's effect on the expression of survivin should be carried out.